Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 4 2Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 6Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Influenza, Human 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Sarcoma 1Recurrence 1Psoriasis 1Papillomavirus Infections 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Melanoma 1Medullary cystic kidney disease 1 1Lung Neoplasms 1Glioblastoma 1Epstein-Barr Virus Infections 1Diabetes Mellitus, Insulin-Dependent, 12 1Crohn Disease 1Condylomata Acuminata 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 6Radiotherapy, Intensity-Modulated 5Cisplatin 5Carboplatin 5Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4artesunic acid 3artemisinin 3Paclitaxel 3Human Papillomavirus Recombinant Vaccine nonavalent 3artenimol 2Vaccines, Synthetic 2Taxes 2Radiation 2Imiquimod 2GX-188 vaccine 2Docetaxel 2Albumin-Bound Paclitaxel 2utomilumab 1toripalimab 1polyphenon E 1infigratinib 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Viusid 1Vaccines 1VP-102 1Therapies, Investigational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Papillomavirus Infections × Vaccines × Clear all
NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 2 Completed
780 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡